GleamWall
中文EN

SRPT Sarepta Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 873303 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-18.9%
TTM net income YoY19.4%
TTM EPS YoY19.9%
Revenue 3-yr CAGR21.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2.5%
Net margin-5.9%
FCF margin9.0%
EBITDA margin-0.9%

Returns

ROE-7.6%
ROA-3.4%
ROIC (approx.)-2.5%
Asset turnover0.59x

Leverage & solvency

Liabilities / assets51.7%
Debt / equity0.66x
Current ratio3.46x
Interest coverage0.62x

Cash quality & payout

Operating cash flow / net income-1.62x
Accruals ratio-9.0%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$2.20B$1.90B
Cost of revenue$25.50M—
Gross profit$2.17B—
R&D expense$1.52B$804.52M
SG&A expense$491.72M$557.87M
Operating income-$699.78M$218.08M
Interest expense-$38.14M-$18.39M
Pretax income-$702.23M$260.77M
Income tax$11.19M$25.54M
Net income-$713.41M$235.24M
EBITDA-$655.26M$255.81M
EPS (basic)-7.132.47
EPS (diluted)-7.132.34
Weighted avg. shares (diluted)100.12M107.88M
Balance sheet
Cash & equivalents$801.28M$1.12B
Short-term investments$138.37M$251.78M
Receivables$398.23M$601.99M
Inventory$914.74M$749.96M
Current assets$2.54B$3.07B
PP&E, net$345.12M$340.34M
Intangibles$28.95M$26.89M
Total assets$3.35B$3.96B
Current liabilities$1.10B$731.68M
Short-term debt$0$0
Long-term debt$828.97M$1.14B
Total debt$828.97M$1.14B
Total liabilities$2.21B$2.44B
Shareholders' equity$1.14B$1.53B
Net debt$27.69M$18.54M
Shares outstanding104.96M96.90M
Cash flow statement
Operating cash flow-$205.48M-$205.79M
Capital expenditure$101.97M$136.96M
Free cash flow-$307.45M-$342.74M
Investing cash flow$69.64M$755.56M
Financing cash flow-$168.34M$124.81M
Depreciation & amortization$44.52M$37.72M
Stock-based compensation$123.40M$184.30M
Share buybacks$25.01M$0

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.